Table 2 Treatment regimens of 271 treated patients with chronic HBV infection
| Â | Treatment duration before the test time (months) | TMF monotherapy 25Â mg QD (patients) | TDF monotherapy 300Â mg QD (patients) | TAF monotherapy 25Â mg QD (patients) | ETV monotherapy 25Â mg QD (patients) | AFD monotherapy 10Â mg QD (patients) | TMF/ETV combination 25Â mg QD/25Â mg QD (patients) |
|---|---|---|---|---|---|---|---|
R (NUC) |  < 6 | 9 |  |  |  |  |  |
CHB (NUCs) |  < 3 | 20 | 12 | 11 | 4 |  | 1 |
3–12 | 9 | 7 | 7 | 3 | 1 | 2 | |
12–24 | 17 | 10 | 5 | 6 |  |  | |
24–48 | 9 | 3 | 4 | 6 | 1 |  | |
 > 48 | 10 | 3 | 10 | 6 |  |  | |
CHB (NUCs/pegIFN) | NUCs: 3–12 pegIFN: < 6 (180 μg QW) | 5 | 6 | 9 | 1 |  |  |
LC (NUCs) |  < 3 | 1 |  | 9 |  |  |  |
3–12 | 2 |  | 1 |  |  |  | |
12–24 | 1 | 2 | 5 | 2 |  | 2 | |
24–48 | 5 | 2 | 1 | 8 | 1 |  | |
 > 48 |  |  | 4 | 4 |  |  | |
HCC (NUCs) |  < 3 | 1 | 2 |  |  |  |  |
3–12 |  |  | 3 | 3 |  |  | |
12–24 |  |  | 2 | 4 |  |  | |
24–48 |  |  |  | 1 |  |  | |
 > 48 | 1 |  | 4 | 2 |  | 1 |